Cart
sales@molnova.com
R1487
CAS No. 449811-92-1
R1487( —— )
Catalog No. M20961 CAS No. 449811-92-1
R1487 is an orally bioavailable and highly selective p38α mitogen-activated protein kinase inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 283 | In Stock |
|
| 10MG | 430 | In Stock |
|
| 25MG | 710 | In Stock |
|
| 50MG | 977 | In Stock |
|
| 100MG | 1321 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameR1487
-
NoteResearch use only, not for human use.
-
Brief DescriptionR1487 is an orally bioavailable and highly selective p38α mitogen-activated protein kinase inhibitor.
-
DescriptionR1487 is an orally bioavailable and highly selective p38α mitogen-activated protein kinase inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38α
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number449811-92-1
-
Formula Weight388.36
-
Molecular FormulaC19H18F2N4O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Dunford E C Herbst E A Jeoung N H et al. PDH activation during in vitro muscle contractions in PDH kinase 2 knockout mice: Effect of PDH kinase 1 compensation[J]. American Journal of Physiology Regulatory Integrative & Comparative Physiology 2011 300(6):R1487.
molnova catalog
related products
-
TAK1-IN-3
TAK1-IN-3 is a novel ATP-competitive TAK1 inhibitor for the study of cancer.
-
JNJ-49095397
JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively.
-
NJK14047
NJK14047 is a novel potent, selective p38 MAPK inhibitor with IC50 of 27 nM against p38α.
